90 related articles for article (PubMed ID: 20844878)
1. Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.
Fransvea E; Mazzocca A; Santamato A; Azzariti A; Antonaci S; Giannelli G
Cancer Chemother Pharmacol; 2011 Jul; 68(1):79-86. PubMed ID: 20844878
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
[TBL] [Abstract][Full Text] [Related]
3. Polyelectrolyte capsules as carriers for growth factor inhibitor delivery to hepatocellular carcinoma.
Baldassarre F; Vergaro V; Scarlino F; De Santis F; Lucarelli G; Torre AD; Ciccarella G; Rinaldi R; Giannelli G; Leporatti S
Macromol Biosci; 2012 May; 12(5):656-65. PubMed ID: 22392760
[TBL] [Abstract][Full Text] [Related]
4. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.
Fransvea E; Mazzocca A; Antonaci S; Giannelli G
Hepatology; 2009 Mar; 49(3):839-50. PubMed ID: 19115199
[TBL] [Abstract][Full Text] [Related]
5. Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway.
Wang Y; Wu J; Lin B; Li X; Zhang H; Ding H; Chen X; Lan L; Luo H
Toxicology; 2014 Dec; 326():9-17. PubMed ID: 25268046
[TBL] [Abstract][Full Text] [Related]
6. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.
Mazzocca A; Fransvea E; Dituri F; Lupo L; Antonaci S; Giannelli G
Hepatology; 2010 Feb; 51(2):523-34. PubMed ID: 19821534
[TBL] [Abstract][Full Text] [Related]
8. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
[TBL] [Abstract][Full Text] [Related]
9. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Li HY; Wang Y; Heap CR; King CH; Mundla SR; Voss M; Clawson DK; Yan L; Campbell RM; Anderson BD; Wagner JR; Britt K; Lu KX; McMillen WT; Yingling JM
J Med Chem; 2006 Mar; 49(6):2138-42. PubMed ID: 16539403
[TBL] [Abstract][Full Text] [Related]
10. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation.
Ching YP; Leong VY; Lee MF; Xu HT; Jin DY; Ng IO
Cancer Res; 2007 Apr; 67(8):3601-8. PubMed ID: 17440071
[TBL] [Abstract][Full Text] [Related]
11. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
12. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.
Okano J; Nagahara T; Matsumoto K; Murawaki Y
Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):543-51. PubMed ID: 18346049
[TBL] [Abstract][Full Text] [Related]
13. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
Soncini C; Carpinelli P; Gianellini L; Fancelli D; Vianello P; Rusconi L; Storici P; Zugnoni P; Pesenti E; Croci V; Ceruti R; Giorgini ML; Cappella P; Ballinari D; Sola F; Varasi M; Bravo R; Moll J
Clin Cancer Res; 2006 Jul; 12(13):4080-9. PubMed ID: 16818708
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
Kaufmann R; Rahn S; Pollrich K; Hertel J; Dittmar Y; Hommann M; Henklein P; Biskup C; Westermann M; Hollenberg MD; Settmacher U
J Cell Physiol; 2007 Jun; 211(3):699-707. PubMed ID: 17323377
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
16. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
18. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
19. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]